article thumbnail

Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability

STAT

Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

article thumbnail

Opinion: STAT+: 3 keys to successful biopharma-academia drug development collaborations

STAT

Academia can be an excellent source of novel drug targets and new technologies that can enhance medicinal discovery. Indeed, academic inventors or founders contributed to more than one-quarter of all medicines approved from 2001 through 2019. Yet many sponsored research collaborations that hope to tap into academia fail.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roivant joins RNA splicing push with Eisai deal

pharmaphorum

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . In preclinical testing, H3b-8800 showed antitumour activity by modulating the disruption of mRNA splicing in cancer, it said.

article thumbnail

Nuclear Pharmacist by Day, DJ by Night

Pharmacy Is Right For Me

There are so many different types of careers within the field of pharmacy—from research and drug development to pharmacy informatics! I worked in Dallas from 95-2001, then moved to NYC, then years later went to the University of Colorado for the NTPD program and received the PharmD. What led you to this career path?

Hospitals 130
article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

But what are the key potential changes and how could they impact drug developers and manufacturers? He noted that within the proposals, there is likely to be a differentiation in incentives for drug development in the orphan and unmet medical need areas. Key areas of potential legislative change. Future outlook.

article thumbnail

Achieving scale up success under economic uncertainty

European Pharmaceutical Review

In 2001 and 2007, through 2009, the economy was hit hard. There was a significant slowdown in drug development, clinical trials, and new drugs coming to market. EMA prepares for winter antibiotic shortages That slowdown resulted in 211 drug shortages in 2010—the highest number recorded in a single year at the time.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 13 Currently, over 350 herbal remedies have been granted a THR licence.